Inventor · disambiguated record
Sanjeev Redkar
Also filed as: REDKAR SANJEEV · REDKAR SANJEEV G
26 granted patents·21 pending applications·256 citations·filing 2002–2022
97Inventor score
Files withSUPERGEN INC20ASTEX PHARMACEUTICALS INC9OTSUKA PHARMA CO LTD4PHIASIVONGSA PASIT3REDKAR SANJEEV3
Top patents by PatentIndex Score
47 records- 0198US7700567B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinSUPERGEN INC·Filed 2005·Granted Apr 20, 2010·26 cites·20 claims
- 0297US7250416B2Azacytosine analogs and derivativesSUPERGEN INC·Filed 2005·Granted Jul 31, 2007·25 cites·43 claims
- 0394US9480698B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinASTEX PHARMACEUTICALS INC·Filed 2015·Granted Nov 1, 2016·8 cites·17 claims
- 0494US9358248B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinASTEX PHARMACEUTICALS INC·Filed 2013·Granted Jun 7, 2016·8 cites·27 claims
- 0594US8461123B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinPHIASIVONGSA PASIT·Filed 2010·Granted Jun 11, 2013·11 cites·21 claims
- 0692US7939546B2Quinoline derivatives for modulating DNA methylationSUPERGEN INC·Filed 2009·Granted May 10, 2011·14 cites·17 claims
- 0791US10456415B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinASTEX PHARMACEUTICALS INC·Filed 2016·Granted Oct 29, 2019·3 cites·46 claims
- 0891US6482830B1Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereforSUPERGEN INC·Filed 2002·Granted Nov 19, 2002·27 cites·22 claims
- 0989US7135464B2Method of administering decitabineSUPERGEN INC·Filed 2004·Granted Nov 14, 2006·33 cites·11 claims
- 1087US9913856B2Drug formulationsASTEX PHARMACEUTICALS INC·Filed 2016·Granted Mar 13, 2018·6 cites·14 claims
- 1186US6710195B2Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositionsSUPERGEN INC·Filed 2002·Granted Mar 23, 2004·21 cites·70 claims
- 1285US10485764B2Lyophilized pharmaceutical compositionsOTSUKA PHARMA CO LTD·Filed 2016·Granted Nov 26, 2019·4 cites·36 claims
- 1385US7790746B2Quinoline derivatives for modulating DNA methylationSUPERGEN INC·Filed 2007·Granted Sep 7, 2010·10 cites·16 claims
- 1485US6982253B2Liquid formulation of decitabine and use of the sameSUPERGEN INC·Filed 2002·Granted Jan 3, 2006·21 cites·79 claims
- 1583US9381207B2Drug formulationsJOSHI-HANGAL RAJASHREE·Filed 2012·Granted Jul 5, 2016·9 cites·40 claims
- 1682US6492379B1Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereforSUPER GEN INC·Filed 2002·Granted Dec 10, 2002·9 cites·23 claims
- 1780US10517886B2Drug formulationsASTEX PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·2 cites·12 claims
- 1879US10933079B2Oligonucleotide analogues incorporating 5-aza-cytosine thereinASTEX PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·0 cites·15 claims
- 1978US7144873B2Kit for delivering decitabine in vivoSUPERGEN INC·Filed 2004·Granted Dec 5, 2006·9 cites·14 claims
- 2077US2022000900A1Oligonucleotide Analogues Incorporating 5-Aza-Cytosine ThereinASTEX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2175US11058705B2Drug formulationsASTEX PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·0 cites·19 claims
- 2275US6696458B2Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereofSUPER GEN INC·Filed 2002·Granted Feb 24, 2004·4 cites·36 claims
- 2374US7071202B2Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereforSUPERGEN INC·Filed 2002·Granted Jul 4, 2006·4 cites·11 claims
- 2470US6756381B2Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereofSUPERGEN INC·Filed 2002·Granted Jun 29, 2004·2 cites·19 claims
- 2568US2022016033A1Lyophilized pharmaceutical compositionsOTSUKA PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2666US7820684B2Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using sameSUPERGEN INC·Filed 2008·Granted Oct 26, 2010·0 cites·13 claims
- 2766US2020093748A1Lyophilized pharmaceutical compositionsOTSUKA PHARMA CO LTD·Filed 2019·Application pending·0 cites
- 2861US2010062992A1Salts of 5-AzacytidineSUPERGEN INC·Filed 2009·Application pending·0 cites
- 2961US2006217407A1Compositions and Formulations of 9-Nitrocamptothecin Polymorphs and Methods of Use ThereforREDKAR SANJEEV·Filed 2006·Application pending·0 cites
- 3059US2010129320A1Quinoline derivatives for modulating dna methylationSUPERGEN INC·Filed 2009·Application pending·0 cites
- 3158US8445502B2Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using sameBEARSS DAVID J·Filed 2010·Granted May 21, 2013·0 cites·8 claims
- 3256US2024218453A1Diagnostic and treatment of cancer using c-met inhibitorAPOLLOMICS INC·Filed 2022·Application pending·0 cites
- 3356US2006205687A1Azacytosine analogs and derivativesPHIASIVONGSA PASIT·Filed 2006·Application pending·0 cites
- 3455US7049322B2Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereforSUPERGEN INC·Filed 2002·Granted May 23, 2006·0 cites·12 claims
- 3554US2006063735A1Salts of 5-azacytidineSUPERGEN INC·Filed 2004·Application pending·0 cites
- 3654US2008175814A1Quinoline derivatives for modulating dna methylationSUPERGEN INC·Filed 2007·Application pending·0 cites
- 3754US2006069060A1Salts of decitabineREDKAR SANJEEV·Filed 2004·Application pending·0 cites
- 3852US2004167205A1Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositionsSUPERGEN INC·Filed 2004·Application pending·0 cites
- 3952US2004162263A1Pharmaceutical formulations targeting specific regions of the gastrointesinal tractSUPERGEN INC A DELAWARE CORP·Filed 2003·Application pending·0 cites
- 4051US2006074046A1Oral administration of decitabine saltREDKAR SANJEEV·Filed 2005·Application pending·0 cites
- 4151US2005267056A1Synthesis and manufacture of pentostatin and its precursors, analogs and derivativesPHIASIVONGSA PASIT·Filed 2004·Application pending·0 cites
- 4249US2022252603A1Method for treating cancer patients using c-met inhibitorAPOLLOMICS INC HANGZHOU·Filed 2020·Application pending·0 cites
- 4348US2023338294A1Novel pharmaceutical formulation for c-met inhibitorAPOLLOMICS INC·Filed 2021·Application pending·0 cites
- 4447US2006014949A1Compositions and formulations of decitabine polymorphs and methods of use thereofSUPERGEN INC·Filed 2004·Application pending·0 cites
- 4544US2011256092A1Quinoline derivatives for modulating dna methylationSUPERGEN INC·Filed 2011·Application pending·0 cites
- 4639US2017360791A1Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugsASTEX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4739US2018169117A1Pharmaceutical formulation comprising a substituted phenyl - (1,3-dihydro-isoindol-2-yl) - methanoneOTSUKA PHARMA CO LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →